US EditionWhite House defends FDA chief against ‘uninformed attacks’ over review of abortion pill
Pro-life groups claim FDA delayed mifepristone review to avoid election impact; 70% of likely voters support requiring doctor visits for abortion drugs, a poll found.
- On Tuesday, the White House defended FDA Commissioner Marty Makary, saying he is working diligently on a 'Gold Standard Science' study and has the administration's utmost confidence.
- A pro-life group on Tuesday demanded FDA Commissioner Makary's removal, alleging the agency delayed the mifepristone review over midterm-election concerns.
- A senior FDA official told RealClearPolitics the study is not being 'slow walked,' while HHS spokesman Andrew Nixon noted legal limits on generic approvals and Robert F. Kennedy Jr. said a review is in progress.
- Activists say the Bloomberg report and alleged delays have angered anti‑abortion activists, who feel alienated despite Marty Makary remaining in President Trump's good graces and the White House asking for patience.
- Next month the FDA approved a generic mifepristone, and prescriptions surged after the Supreme Court 2022 abortion ruling as nearly two-thirds of abortions are now medication abortions.
14 Articles
14 Articles
Trump Administration Says Abortion Pill Study Not Being ‘Slow-Walked’
The Trump administration on Dec. 10 denied allegations that its study on the safety of an abortion pill has been slowed down. Bloomberg News had reported this week, citing anonymous sources, that Food and Drug Administration Commissioner Dr. Marty Makary recently directed regulators to delay the study of mifepristone until after the 2026 midterm elections. “The study is not being ‘slow walked,'” a White House official told The Epoch Times. “Comp…
FDA Commissioner Marty Makary Promises Thorough Review of Abortion Pill Dangers
Food and Drug Administration Commissioner Marty Makary is promising a thorough review of the risks and dangers associated with the abortion pill. That’s in response to pro-life advocates calling for his resignation after reports surfaced that the FDA was slow-walking the review of mifepristone until after the elections. As LifeNews reported, pro-life groups are accusing him of stalling a critical safety review of the dangerous abortion drug mife…
Real Clear Politics
WH Ignores Demands From Pro Life Lobby To Fire FDA Commissioner
The pro-life lobby is calling on President Trump to fire FDA Commissioner Marty Makary after news broke alleging that the agency is slow walking a long-promised review of the abortion drug...
Coverage Details
Bias Distribution
- 77% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
